MetaVia (MTVA) Cash from Operations (2015 - 2025)
MetaVia's (MTVA) quarterly Cash from Operations came in at 4860000.0 in Q4 2025, up 11.14% YoY from 4373040.47 in Q4 2024, and down 64.47% on a QoQ basis from 2955000.0 in Q3 2025.
MetaVia (MTVA) Cash from Operations (2015 - 2025) Analysis & Trends
MetaVia (MTVA) has 11 years of Cash from Operations data on file, last reported at 4860000.0 in Q4 2025.
- Quarterly Cash from Operations rose 11.14% year-over-year to 4860000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15701000.0 (up 36.46% YoY) and the FY2025 annual result came in at 15701000.0, up 36.46% from the prior year.
- Cash from Operations declined to 4860000.0 in Q4 2025, from 2955000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1807000.0 in Q4 2022 to a low of 7251000.0 in Q2 2024.
- A 5-year average of 3902800.0 and a median of 3239500.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 254.57% — and 2025, when it soared 57.44%.
- Tracing MTVA's Cash from Operations over 5 years: stood at 2899000.0 in 2021, then surged by 37.67% to 1807000.0 in 2022, then sank by 87.77% to 3393000.0 in 2023, then sank by 61.18% to 5469000.0 in 2024, then rose by 11.14% to 4860000.0 in 2025.
- The last three Cash from Operations figures came in at 4860000.0 (Q4 2025), 2955000.0 (Q3 2025), and 3086000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.86 Mn |
| Dec 31, 2025 | -4.86 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -3.09 Mn |
| Jun 30, 2025 | -3.09 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Dec 31, 2024 | -5.47 Mn |
| Dec 31, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.55 Mn |
| Sep 30, 2024 | -5.55 Mn |
| Jun 30, 2024 | -7.25 Mn |
| Jun 30, 2024 | -7.25 Mn |
| Mar 31, 2024 | -6.44 Mn |
| Mar 31, 2024 | -6.44 Mn |
| Dec 31, 2023 | -3.39 Mn |
| Dec 31, 2023 | -3.39 Mn |
| Sep 30, 2023 | -2.81 Mn |
| Sep 30, 2023 | -2.81 Mn |